Publications (34) Ana Belén Herrero Hernández publications

2024

  1. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

  2. TRIM33 loss in multiple myeloma is associated with genomic instability and sensitivity to PARP inhibitors

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. Autophagy, Oxidative Stress, and Alcoholic Liver Disease: A Systematic Review and Potential Clinical Applications

    Antioxidants, Vol. 12, Núm. 7

  2. DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities

    Cancers, Vol. 15, Núm. 2

2022

  1. Chloroquine-Induced DNA Damage Synergizes with Nonhomologous End Joining Inhibition to Cause Ovarian Cancer Cell Cytotoxicity

    International Journal of Molecular Sciences, Vol. 23, Núm. 14

  2. Panobinostat Synergistically Enhances the Cytotoxicity of Microtubule Destabilizing Drugs in Ovarian Cancer Cells

    International Journal of Molecular Sciences, Vol. 23, Núm. 21

  3. RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation

    Experimental Hematology and Oncology, Vol. 11, Núm. 1

  4. Recurrent NOMO1 Gene Deletion Is a Potential Clinical Marker in Early-Onset Colorectal Cancer and Is Involved in the Regulation of Cell Migration

    Cancers, Vol. 14, Núm. 16

2021

  1. Microtubule destabilizing sulfonamides as an alternative to taxane-based chemotherapy

    International Journal of Molecular Sciences, Vol. 22, Núm. 4, pp. 1-21

  2. Synergistic effect of Chloroquine and Panobinostat in ovarian cancer through induction of DNA damage and inhibition of DNA repair

    Neoplasia (United States), Vol. 23, Núm. 5, pp. 515-528

2020

  1. CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition

    Leukemia, Vol. 34, Núm. 6, pp. 1599-1612

  2. FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma

    Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 7, pp. 4171-4182

2019

  1. Factors regulating microRNA expression and function in multiple myeloma

    Non-coding RNA, Vol. 5, Núm. 1

2017

  1. DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

  2. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair

    Journal of Hematology and Oncology, Vol. 10, Núm. 1

  3. Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bor tezomib and dexamethasone

    Haematologica, Vol. 102, Núm. 1, pp. 168-175

  4. Targeting ongoing DNA damage in multiple myeloma: Effects of DNA damage response inhibitors on plasma cell survival

    Frontiers in Oncology, Vol. 7, Núm. MAY

2016

  1. Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma

    American Journal of Pathology, Vol. 186, Núm. 8, pp. 2171-2182

  2. Expression of MLL-AF4 or AF4-MLL fusions does not impact the efficiency of DNA damage repair

    Oncotarget, Vol. 7, Núm. 21, pp. 30440-30452

  3. Molecular mechanisms of p53 deregulation in cancer: An overview in multiple myeloma

    International Journal of Molecular Sciences, Vol. 17, Núm. 12